INTRODUCTION
Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection for satisfactory sexual performance. 1 ED can have a neurogenic, psychogenic or endocrine basis; however, a common underlying cause is thought to be related to vascular abnormalities of the penile blood supply and erectile tissue. Studies indicate that ED is correlated with increased age, cardiovascular disease, diabetes, hypertension, smoking and depression. [2] [3] [4] ED must be considered a multidimensional disorder deriving from a general (or stepwise) perturbation of the organic (the body), relational (the couple) and intrapsychic (the mind) components of the erectile response. [5] [6] [7] Oral phosphodiesterase type 5 (PDE5) inhibitors are recommended as a first-line therapy for EDs of varying etiology and severity. 8, 9 However, many patients are dissatisfied with the available therapies due to their high cost, adverse events (AEs) and perceived lack of efficacy. 10 PDE5 plays an important role in regulating nitric oxide-mediated smooth muscle relaxation. PDE5 inhibitors are similar in structure to cGMP and competitively bind to PDE5. This binding inhibits the hydrolysis of cGMP, allowing for the accumulation of cGMP levels and leading to penile erection. 11 Avanafil, a PDE5 inhibitor, is highly selective for PDE5 and highly potent, with a 50% inhibitory concentration of 4.3-5.2 nmol l −1 . 12−14 It has higher selectivity (120-fold) against PDE6 than sildenafil (16-fold) and vardenafil (21-fold), as well as much higher selectivity (>10 000-fold) against PDE1 compared with ORIGINAL ARTICLE Avanafil for male erectile dysfunction: a systematic review and meta-analysis was used for the meta-analysis. If the same group of researchers studied a group of subjects with multiple experiments, then each study was included. A flow diagram of the study selection process is presented in Figure 1 .
Quality assessment
The quality of the retrieved RCTs, which included assessment of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting of outcomes and other possible sources of bias, was assessed using the Jadad scale. 16 All of the identified RCTs were included in the meta-analysis, regardless of the quality score. The methodological quality of each study was assessed according to how patients were allocated to the arms of the study, the concealment of allocation procedures, blinding and data loss due to attrition. The studies were then classified qualitatively according to the guidelines published in the Cochrane Handbook for Systematic Reviews of Interventions v. 5.1.0. 17 Based on the quality assessment criteria, each study was rated and assigned to one of the three following quality categories: A, if all quality criteria were adequately met, the study was deemed to have a low risk of bias; B, if one or more of the quality criteria was only partially met or was unclear, the study was deemed to have a moderate risk of bias; or C, if one or more of the criteria was not met or not included, the study was deemed to have a high risk of bias. Differences were resolved by discussion among the authors.
Data extraction
The following information was collected for each study: (i) the name of the first author and the publication year, (ii) the study design and sample size, (iii) the therapy that the patients received, (iv) the country in which the study was conducted and (v) data including the successful vaginal penetration (SEP2), successful intercourse (SEP3), headache, flushing and discontinuations due to AEs.
Statistical analysis and meta-analysis
The meta-analysis of comparable data was carried out using RevMan v. 5.1.0 (Cochrane Collaboration, Oxford, UK). 17 Changes in the SEP2, SEP3, headache, flushing and discontinuations due to AEs were determined as differences between the baseline (study entry) and study completion. We estimated the relative risk for dichotomous outcomes and the standardized mean difference (SMD) for continuous outcomes pooled across studies by using the DerSimonian and Laird random-effects model. 18 We used a 95% confidence interval (CI). If the results of the analysis showed P > 0.05, we considered the studies homogeneous and chose a fixed-effect model for the meta-analysis. Otherwise, a random-effect model was used. We quantified the inconsistencies using the I² statistic, which indicates the proportion of heterogeneity across studies that is not due to chance, thereby describing the extent of true inconsistency in the results across trials. 18 I² < 25% reflects a small level of inconsistency and I² > 50% reflects significant inconsistency.
RESULTS

Characteristics of the individual studies
The database search found 51 articles that could have been included in our meta-analysis. Based on the inclusion and exclusion criteria, 36 articles were excluded after reading the titles and abstracts of the articles. Nine articles were not RCTs. Two articles lacked useful data. In all, four articles, 19−22 reporting data from a total of four RCTs that compared avanafil with placebo, were included in the analysis (Figure 1) . The baseline characteristics of the studies included in our meta-analysis are listed in Table 1 .
Quality of the individual studies
All four RCTs were double blinded and all described the randomization processes that they had used. All included a power calculation to determine the optimal sample size ( Table 2 ). The level of quality of each identified study was A. The funnel plot provided a qualitative estimation of the publication bias of the studies and no evidence of bias was found (Figure 2 ).
Successful vaginal penetration
The four RCTs represented 889 participants (445 in the avanafil 100 mg group and 444 in the control group) (Figure 3 ). According to our analysis, no heterogeneity was found among the trials (Figure 3 ) and the effect size for the meta-analysis was denoted as the odds ratio (OR). The pooled estimate of OR was 5.06 and the 95% CI was 3.29-7.78 (P < 0.00001). This result suggests that avanafil showed statistically significant improvement in the SEP2 compared with placebo.
Successful intercourse
The four RCTs represented 889 participants (445 in the avanafil 100 mg group and 444 in the control group) (Figure 3) . No heterogeneity was found among the trials (Figure 3) . The pooled estimate of the OR was 3.99 and the 95% CI was 2.80-5.67 (P < 0.00001). This result suggests that avanafil showed statistically significantly greater improvement in the SEP3 compared with placebo.
Discontinuation due to adverse events
The four RCTs included data on discontinuation due to AEs and represented a cohort of 916 participants (457 in the avanafil 100 mg group and 459 in the control group) (Figure 4) . The pooled estimate of the OR was 1.48 and the 95% CI was 0.54-4.08 (P = 0.44). These results suggest that avanafil and the placebo are similar in terms of the incidence of discontinuation due to AEs.
Treatment-emergent AEs (TEAEs)
Three RCTs, representing 778 participants (387 in the avanafil group and 391 in the control group), included TEAEs data (Figure 4) . The pooled estimate of the OR was 1.97 and the 95% CI = 1.45-2.68, P < 0.0001. These results suggest that TEAEs with avanafil were significantly less likely to occur with the placebo. 
Headache and flushing
Four RCTs included the headache data, representing a cohort of 916 participants (457 in the avanafil 100 mg group and 459 in the control group) (Figure 4) . The pooled estimate of the OR was 5.48 and the 95% CI was 2.18-13.78 (P = 0.0003). The four RCTs also included the flushing data, representing a cohort of 916 participants (457 in the avanafil 100 mg group and 459 in the control group) (Figure 4) . The pooled estimate of the OR was 8.12 and the 95% CI was 2.62-25.13 (P = 0.0003). These results suggest that the specific AEs with avanafil, including headache and flushing, were significantly less likely to occur with the placebo. 
Sensitivity analysis
Sensitivity analysis was performed by dividing the included studies into a US and an Asian group. Our analysis indicated that avanafil showed statistically significant improvement in the SEP2 (OR = 6.67, 95% CI = 4.01 to 11.12, P<0.00001 and OR = 2.02, 95% CI = 0.85 to 4.77, P = 0. 01) and SEP 3 (OR = 4.15, 95% CI = 2.78 to 6.21, P<0.00001 and OR = 3.44, 95% CI = 1.66 to 7.13, P = 0. 0009) groups in both the US and the Asian group. No differences were found between the avanafil 100 mg and avanafil 200 mg groups regarding changes in the SEP2 (OR = 0.88, 95% CI = 0.64-1.22, P = 0.45 and OR = 0.89, 95% CI = 0.42-1.90, P = 0. 76, respectively) or SEP3 (OR = 0.86, 95% CI = 0.63-1.17, P = 0.34 and OR = 0.94, 95% CI = 0.47-1.85, P = 0. 85, respectively) in either the US or the Asian group.
DISCUSSION
ED affects 30 million men in the United States and 150 million worldwide. This number is expected to increase as the population ages. 23 ED occurs more often in males with diabetes, heart disease, previous radical prostatectomy and neurologic conditions. ED is also associated with cardiovascular risk factors, including hypertension, diabetes, dyslipidemia, chronic kidney disease and obesity. 24 The PDE5 inhibitors have been shown to restore penile blood flow and erections in response to sexual stimulation. 25 Despite these options, many men suffering from ED fail to respond clinically. Most of these men are patients with severe ED involving diabetes mellitus, severe vascular insufficiency or postprostatectomy complications. Newer medications in the PDE5 inhibitor class that have greater efficacy and lower adverse reaction profiles are being studied. 23 Avanafil is a novel PDE5 inhibitor that has been shown to have a greater selectivity for PDE5 and a higher selectivity against PDE1 and PDE6. 19 This systematic review and quantitative meta-analysis summarizes the evidence from randomized controlled clinical trials regarding the efficacy and safety of avanafil for the treatment of ED. Overall, compared with men receiving placebos, those allocated to the avanafil group had a higher percentage of SEP2 and were more likely to have SEP3. Compared with the meta-analysis of PDE5 inhibitors, 26 avanafil (2.78-fold of placebo) performed significantly better than sildenafil (1.94-fold of placebo), vardenafil (1.94-fold of placebo) or tadalafil (2.09-fold of placebo) with regard to SEP3 improvement. Moreover, treatment with 100 mg avanafil was associated with significant improvements in the International Index of Erectile Function-erectile function (IIEF-EF) domain score compared with placebo in the primary efficacy end points across all included RCTs. In addition, significant improvements in key secondary efficacy end points of each domain of IIEF (orgasmic function, intercourse satisfaction, sexual desire and overall satisfaction) were observed for the avanafil treatment group compared with placebo.
Safety data from the trials in this meta-analysis suggest that avanafil administration was generally well-tolerated. Although TEAEs were significantly more frequent with avanafil use than with placebo, they were mostly mild or moderate in severity and discontinuation due to AEs occurred no more frequently with avanafil use than with placebo. The most commonly reported TEAEs were headache and flushing, but they were all well-tolerated. All of the included RCTs indicated no clinically significant changes in laboratory tests, electrocardiograms or blood pressure in the avanafil groups.
All four of the included RCTs showed that avanafil 100 and 200 mg are similarly effective for a large proportion of patients with ED ( Figure 5) . The safety profile of avanafil 100 mg appears to be comparable with that of avanafil 200 mg, with similar side effects being present. Patients who took avanafil 200 mg were more likely to have a headache (Figure 5 ). Men were instructed to take the study drug approximately 30 min before the initiation of sexual activity in all of the included RCTs. Combined with the effective results, the onset of action of avanafil appears to be shorter than that of sildenafil. The unique clinical properties (higher selectivity and faster onset) of avanafil will provide a welcome addition to current ED management strategies. Compared with the meta-analysis of PDE5 inhibitors, 26 the incidence of headache and flushing while taking avanafil (6.1% vs 1.1% and 5.5% vs 0.4%, respectively) was much lower than with sildenafil (14.2% vs 4.3% and 11.4% vs 1.6%), vardenafil (10.6% vs 2.5% and 10.0% vs 0.8%) and tadalafil (11.0% vs 3.0% and 4.0% vs 1.1%). Only two cases of vision abnormality were discovered in the four included RCTs. The rate was much lower than that for sildenafil. 27 These observed AE data for avanafil might be correlated with its favorable pharmacokinetic profile and greater selectivity for PDE5. Avanafil has a higher selectivity (120-fold) against PDE6 than sildenafil (16-fold) and vardenafil (21-fold), as well as a much higher selectivity (>10 000-fold) against PDE1 than sildenafil (380-fold) or vardenafil (1000-fold). Avanafil does not inhibit PDE11. Color vision disturbances are believed to be attributable to the nonspecific inhibition of certain PDE inhibitors, specifically PDE6. 28 The studies included in the present meta-analysis all derived their data from randomized, double-blind, placebo-controlled trials. According to the quality assessment scale that we developed, the quality of the individual studies in the meta-analysis was conforming. The results of this analysis have great importance not only from the scientific standpoint, but also from that of everyday clinical practice. However, few studies were included in this analysis and the long-term safety, efficacy and persistence of avanafil cannot be extrapolated here. In addition, the data from unpublished studies were not included in the analysis and these factors may have resulted in a bias. Additional high-quality trials with larger samples are proposed to learn more about the efficacy and safety of the therapies for ED. 
